Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Nature

Volumn 551, Issue 7681, 2017, Pages S12-S16

  Balachandran, Vinod P ^a   Łuksza, Marta ^b   Zhao, Julia N ^a   Makarov, Vladimir ^a   Moral, John Alec ^a   Remark, Romain ^c   Herbst, Brian ^a   Askan, Gokce ^a   Bhanot, Umesh ^a   Senbabaoglu, Yasin ^d   Wells, Daniel K ^e   Cary, Charles Ian Ormsby ^e   Grbovic Huezo, Olivera ^a   Attiyeh, Marc ^a   Medina, Benjamin ^a   Zhang, Jennifer ^a   Loo, Jennifer ^a   Saglimbeni, Joseph ^a   Abu Akeel, Mohsen ^d   Zappasodi, Roberta ^d   Riaz, Nadeem ^a   Smoragiewicz, Martin ^f   Larkin Kelley, Z ^g,h   Basturk, Olca ^a   Gönen, Mithat ^a   Levine, Arnold J ^b   Allen, Peter J ^a   Fearon, Douglas T ^g,h   Merad, Miriam ^c   Gnjatic, Sacha ^c   Iacobuzio Donahue, Christine A ^a   Wolchok, Jedd D ^a,d,h   Dematteo, Ronald P ^a   Chan, Timothy A ^a   Greenbaum, Benjamin D ^c   Merghoub, Taha ^a,d   Leach, Steven D ^a,i   Johns, Amber L ^j   Scott Mead, R ^j,k   Gill, Anthony J ^j,l   Chang, David K ^j,m   McKay, Skye H ^j   Chantrill, Lorraine A ^j,n   Chin, Venessa T ^j   Chou, Angela ^j,n   Humphris, Jeremy L ^j   Pajic, Marina ^j   Steinmann, Angela ^j   Arshi, Mehreen ^j   Drury, Ali ^j   Froio, Danielle ^j   Morgan, Ashleigh ^j   Timpson, Paul ^j   Hermann, David ^j   Vennin, Claire ^j   Warren, Sean ^j   Pinese, Mark ^j   Wu, Jianmin ^j   Pinho, Andreia V ^j   Tucker, Katherine ^k   Andrews, Lesley ^k   Samra, Jaswinder S ^l   Arena, Jennifer ^l   Pavlakis, Nick ^l   High, Hilda A ^l   Mittal, Anubhav ^l   Biankin, Andrew V ^m   Bailey, Peter ^m   Martin, Sancha ^m   Musgrove, Elizabeth A ^m   Jones, Marc D ^m   Nourse, Craig ^m   Jamieson, Nigel B ^m   Stoita, Alina ⁿ   Williams, David ⁿ   Spigelman, Allan ⁿ   Waddell, Nicola ^o   Pearson, John V ^o   Patch, Ann Marie ^o   Nones, Katia ^o   Newell, Felicity ^o   Mukhopadhyay, Pamela ^o   Addala, Venkateswar ^o   Kazakoff, Stephen ^o   Holmes, Oliver ^o   Leonard, Conrad ^o   Wood, Scott ^o   Xu, Christina ^o   Grimmond, Sean M ^p   Hofmann, Oliver ^p   Wilson, Peter J ^q   Christ, Angelika ^q   Bruxner, Tim ^q   Asghari, Ray ^r   Merrett, Neil D ^r   Pavey, Darren ^r   Das, Amitabha ^r   Goodwin, Annabel ^s,t   Cosman, Peter H ^s   Ismail, Kasim ^s   O’connor, Chelsie ^s   Cooper, Caroline L ^t   Grimison, Peter ^t   Kench, James G ^t   Sandroussi, Charbel ^t   Lam, Vincent W ^u   McLeod, Duncan ^u   Nagrial, Adnan M ^u   Kirk, Judy ^u   James, Virginia ^u   Texler, Michael ^v   Forest, Cindy ^v   Epari, Krishna P ^v   Ballal, Mo ^v   Fletcher, David R ^v   Mukhedkar, Sanjay ^v   Zeps, Nikolajs ^w   Beilin, Maria ^w   Feeney, Kynan ^w   Nguyen, Nan Q ^x   Ruszkiewicz, Andrew R ^x   Worthley, Chris ^x   Chen, John ^y   Brooke Smith, Mark E ^y   Papangelis, Virginia ^y   Clouston, Andrew D ^z   Martin, Patrick ^z   Barbour, Andrew P ^aa   O’rourke, Thomas J ^aa   Fawcett, Jonathan W ^aa   Slater, Kellee ^aa   Hatzifotis, Michael ^aa   Hodgkinson, Peter ^aa   Nikfarjam, Mehrdad ^ab   Eshleman, James R ^ac   Hruban, Ralph H ^ac   Wolfgang, Christopher L ^ac   Hodgin, Mary ^ac   Scarpa, Aldo ^ad   Lawlor, Rita T ^ad   Beghelli, Stefania ^ad   Corbo, Vincenzo ^ad   Scardoni, Maria ^ad   Bassi, Claudio ^ad   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUTE FOR ADVANCED STUDY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Swim Across America Laboratory   (United States)

^e PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Simons Center for Quantitative Biology   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ NORRIS COTTON CANCER CENTER   (United States)

^j GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^k PRINCE OF WALES HOSPITAL   (Australia)

^l ROYAL NORTH SHORE HOSPITAL   (Australia)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ ST VINCENT S HOSPITAL   (Australia)

^o QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

^q UNIVERSITY OF QUEENSLAND   (Australia)

^r BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^s LIVERPOOL HOSPITAL   (Australia)

^t ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^u WESTMEAD HOSPITAL   (Australia)

^v FREMANTLE HOSPITAL   (Australia)

^w ST JOHN OF GOD HOSPITAL   (Australia)

^x ROYAL ADELAIDE HOSPITAL   (Australia)

^y FLINDERS MEDICAL CENTRE   (Australia)

^z Envoi Pathology   (Australia)

^aa PRINCESS ALEXANDRA HOSPITAL   (Australia)

^ab AUSTIN HOSPITAL   (Australia)

^ac DEPARTMENT OF PATHOLOGY   (United States)

^ad UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; EPITOPE; NEOANTIGEN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIGEN; BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; HOMOLOGY; IMMUNITY; MODEL; PEPTIDE; SURVIVAL; TUMOR;

ADULT; AGED; ARTICLE; BIOPHYSICS; CANCER SURVIVOR; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE ACTIVATION; WHOLE EXOME SEQUENCING; ADENOCARCINOMA; BLOOD; COMPUTER SIMULATION; CROSS REACTION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PANCREAS TUMOR; PROGNOSIS; SURVIVAL ANALYSIS;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; BACTERIAL PROTEINS; CA-125 ANTIGEN; CANCER SURVIVORS; COMPUTER SIMULATION; CROSS REACTIONS; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, CYTOTOXIC; WHOLE EXOME SEQUENCING;

EID: 85034815842     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature24462     Document Type: Article

References (27)

1. Ino, Y. et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 108, 914-923 (2013).
2. Hiraoka, N. et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782-1790 (2015).
3. Remark, R. et al. In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Sci. Immunol. 1, aaf6925 (2016).
4. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
5. Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433-438 (2016).
6. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
7. Hundal, J. et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 8, 11 (2016).
8. Witkiewicz, A. K. et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun. 6, 6744 (2015).
9. Zitvogel, L., Ayyoub, M., Routy, B., Kroemer, G. Microbiome and anticancer immunosurveillance. Cell 165, 276-287 (2016).
10. Uksza, M., Lässig, M. A predictive fitness model for influenza. Nature 507, 57-61 (2014).
11. Verdegaal, E. M. E. et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536, 91-95 (2016).
12. Chekmasova, A. A. et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin. Cancer Res. 16, 3594-3606 (2010).
13. Morgado, M. et al. Tumor necrosis factor- A nd interferon-stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NF B. Oncotarget 7, 14871-14884 (2016).
14. Das, S. et al. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget 6, 5772-5787 (2015).
15. Shukla, S. K. et al. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget 6, 19118-19131 (2015).
16. Muniyan, S. et al. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes Cancer 7, 110-124 (2016).
17. Elhanati, Y., Murugan, A., Callan, C. G., Mora, T., Walczak, A. M. Quantifying selection in immune receptor repertoires. Proc. Natl Acad. Sci. USA 111, 9875-9880 (2014).
18. Saito, T. et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679-684 (2016).
19. Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642-1650 (2012).
20. Gross, L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326-333 (1943).
21. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47-52 (2016).
22. Embuscado, E. E. et al. Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol. Ther. 4, 548-554 (2005).
23. Haridas, D. et al. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS One 6, e26839 (2011).
24. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
25. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
26. Deshwar, A. G. et al. PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol. 16, 35 (2015).
27. Dharma Rao, T. et al. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl. Immunohistochem. Mol. Morphol. 18, 462-472 (2010).